On this page
- What a diabetic foot ulcer is
- What standard care does, and why it matters most here
- Why cells are being studied for this
- What the trial evidence shows
- What remains unestablished
- Who might be considered
- Why urgency matters more here than elsewhere
- Practical questions
- Frequently asked questions
- Requesting a medical evaluation
This is one of the few indications outside the knee with a randomised controlled trial behind it, and one of the few where the underlying problem — a wound that will not close — is something cells might plausibly address. Diabetic foot ulcers and stem cell therapy has early human evidence, in a narrow indication, alongside care that works and is often not delivered well.
What a diabetic foot ulcer is
A wound on the foot in someone with diabetes that fails to heal normally. Three things usually combine: reduced sensation from neuropathy, so the injury is not felt; impaired blood supply, so healing material does not arrive; and impaired immune response, so infection takes hold.
The consequences are serious and often underestimated. Foot ulcers precede a large proportion of lower-limb amputations in people with diabetes, and the mortality following major amputation is substantial.
The wound is the visible part of a systemic problem, which is why treating only the wound rarely works. Anything offered as a treatment for the ulcer alone, without reference to circulation, pressure and glucose control, is addressing the symptom of a symptom.
What standard care does, and why it matters most here
Offloading — taking weight off the ulcer, often with a total contact cast — is the single most effective intervention and the most commonly skipped.
Debridement removes dead tissue. Infection is treated, sometimes aggressively. Blood supply is assessed, and revascularisation is considered where perfusion is inadequate, because a wound without blood flow will not heal whatever is put on it.
Glycaemic control, appropriate dressings and specialist podiatry complete the picture. A multidisciplinary foot service improves outcomes more than any single intervention.
Any discussion of cell therapy here belongs alongside all of that, not instead of it. A clinic not asking about your perfusion and your offloading is not assessing the wound.
Why cells are being studied for this
The proposed mechanisms fit the problem better than they do for many indications: modulating the chronic inflammation that stalls these wounds, and promoting the formation of new small blood vessels.
A chronic wound is arguably a failure of a normal healing programme rather than a structural defect, which makes a signalling intervention a more coherent proposal than it is for, say, replacing cartilage.
That is a reason to test, not a result — see MSC immunomodulation.
Worth noting that several other biological wound products have travelled this exact path: promising rationale, encouraging early studies, then disappointing results once trials were large enough and comparison groups received good standard care. That history is a reason for caution rather than dismissal.
What the trial evidence shows
A prospective, randomised and controlled study examined human umbilical cord MSC injection for diabetic foot ulcer — Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcer.
Related work in diabetes more broadly includes a meta-analysis — Meta-analysis shows that mesenchymal stem cell therapy can be a possible treatment for diabetes — where the word “possible” is carrying real weight.
MSC therapy has also been trialled in diabetic kidney disease, a different diabetic complication — Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease.
What remains unestablished
Whether cell therapy adds anything on top of properly delivered standard care, which is the question that matters and the hardest to study.
Whether healed ulcers stay healed. Recurrence rates in this condition are high, and short trial follow-up does not capture it.
Whether amputation rates change — the outcome patients actually care about, and one that requires larger and longer trials than exist.
This is a recurring shape in wound research. Surrogate endpoints such as percentage area reduction at twelve weeks are easier to measure and move more readily than the outcomes that matter, and a treatment can improve the first without touching the second.
Who might be considered
Someone with an ulcer that has failed to progress despite adequate offloading, debridement and infection control, with demonstrably adequate blood supply to the foot.
That last point is not negotiable. If perfusion is the limiting factor, vascular assessment comes first, because no cell preparation compensates for a blocked artery. Ankle-brachial index, toe pressures or duplex imaging are the usual starting points, and any of them is cheaper than a flight.
Active infection, osteomyelitis and critical limb ischaemia all need addressing before anything elective is contemplated. Each of those changes the problem from a wound that is healing slowly into one that is actively getting worse, and the management is entirely different.
Why urgency matters more here than elsewhere
Most conditions discussed on this site are chronic and slow. This one is not. An infected diabetic foot can deteriorate over days.
Travelling abroad for elective treatment while a wound is actively infected is a genuinely bad idea, and any clinic willing to book that without asking is not paying attention.
If the foot is hot, spreading, smelling or systemically unwell, that is local emergency care today rather than a flight next month — see adverse events.
Practical questions
The answers should show that the wound has been assessed as a wound, not as a sales opportunity.
- Has my blood supply been formally assessed, and by whom?
- Is my offloading adequate, and how would you know?
- Has osteomyelitis been excluded?
- What happens to the ulcer while I travel?
- Who manages the wound after I go home?
See type 2 diabetes and cord-derived therapy.
Scar tissue and wound repair covers the wider wound-healing evidence, and peripheral vascular disease covers the arterial supply that has to be assessed before any wound treatment is applied.
Frequently asked questions
Is there real evidence here?
Yes, a prospective randomised controlled trial in this exact indication, which is more than most conditions discussed on this site can claim. Numbers are small and follow-up is short, so it is a starting point rather than a settled answer.
Will this save my foot?
No trial has shown a change in amputation rates. That would need larger and longer studies than currently exist.
What matters most for healing?
Offloading, adequate blood supply and infection control. If perfusion is the limiting factor, no cell preparation compensates for a blocked artery.
Can I travel with an active ulcer?
If it is infected, no. An infected diabetic foot can deteriorate over days, and that needs care where you are, today.
Does it stop ulcers coming back?
Unknown. Recurrence in this condition is high and trial follow-up is too short to measure it.
Should I stop my standard wound care?
No. Cell therapy is discussed alongside offloading, debridement and infection control, never instead of them.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.